Fig. 5: Immune activation effect of oncolytic virus therapies in vitro. | Cancer Gene Therapy

Fig. 5: Immune activation effect of oncolytic virus therapies in vitro.

From: Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model

Fig. 5

4T1 cells were infected with oncolytic viruses for 48 h, and the cells and supernatant were collected separately. A The secretion of GM-CSF in the supernatant. B The expression of PD-L1 in 4T1 cells. We prepared single-cell suspensions of mouse spleen cells and cocultured them with supernatant for 3 days. Then, one fraction of the cells was labelled with panel 1, PE-CD3, FITC-CD4 and APC-CD8, and panel 2, PerCP Cy5.5-CD3 and PE-CD279 (PD-1). C The percentages of PD-1+ and CD8+ T lymphocytes were analysed by flow cytometry. Total RNA was isolated from the other fraction of cells. After cDNA was synthesized, the expression of D Th1 cytokines (IL-2 and INF-γ), E Th2 cytokine (IL-10), F chemokine (CCL5) and G cytotoxicity-related genes (granzyme B and perforin) was analysed by real-time RT-PCR and normalized to β-actin (n = 4/group). The data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus rAd.Null. One-way ANOVA followed by Bonferroni post hoc tests was used.

Back to article page